These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 28501897)

  • 61. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 62. miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas.
    Haemmig S; Baumgartner U; Glück A; Zbinden S; Tschan MP; Kappeler A; Mariani L; Vajtai I; Vassella E
    Cell Death Dis; 2014 Jun; 5(6):e1279. PubMed ID: 24901050
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway.
    Zhang C; Yang X; Fu C; Liu X
    Gene; 2018 Sep; 672():172-179. PubMed ID: 29906532
    [TBL] [Abstract][Full Text] [Related]  

  • 64. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
    Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
    Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
    [TBL] [Abstract][Full Text] [Related]  

  • 65. miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase.
    Chen H; Li X; Li W; Zheng H
    J Transl Med; 2015 Feb; 13():69. PubMed ID: 25890369
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
    Jiang C; Shen F; Du J; Fang X; Li X; Su J; Wang X; Huang X; Liu Z
    Biomed Pharmacother; 2018 Jan; 97():844-850. PubMed ID: 29136760
    [TBL] [Abstract][Full Text] [Related]  

  • 67. MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.
    Han J; Chen Q
    Int J Clin Exp Pathol; 2015; 8(10):12698-707. PubMed ID: 26722459
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
    Atif F; Patel NR; Yousuf S; Stein DG
    PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
    Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
    Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
    [TBL] [Abstract][Full Text] [Related]  

  • 70. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51.
    Zhang N; Wu X; Yang L; Xiao F; Zhang H; Zhou A; Huang Z; Huang S
    Clin Cancer Res; 2012 Nov; 18(21):5961-71. PubMed ID: 22977194
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
    Messaoudi K; Clavreul A; Lagarce F
    Drug Discov Today; 2015 Jul; 20(7):899-905. PubMed ID: 25744176
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma.
    Velpula KK; Guda MR; Sahu K; Tuszynski J; Asuthkar S; Bach SE; Lathia JD; Tsung AJ
    Oncotarget; 2017 May; 8(22):35639-35655. PubMed ID: 28410193
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.
    Munoz JL; Rodriguez-Cruz V; Greco SJ; Ramkissoon SH; Ligon KL; Rameshwar P
    Cell Death Dis; 2014 Mar; 5(3):e1145. PubMed ID: 24675463
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.
    Murphy SF; Varghese RT; Lamouille S; Guo S; Pridham KJ; Kanabur P; Osimani AM; Sharma S; Jourdan J; Rodgers CM; Simonds GR; Gourdie RG; Sheng Z
    Cancer Res; 2016 Jan; 76(1):139-49. PubMed ID: 26542214
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling.
    Hanif F; Perveen K; Malhi SM; Jawed H; Simjee SU
    Toxicol In Vitro; 2018 Oct; 52():306-313. PubMed ID: 30003979
    [TBL] [Abstract][Full Text] [Related]  

  • 77. LINC00511 facilitates Temozolomide resistance of glioblastoma cells via sponging miR-126-5p and activating Wnt/β-catenin signaling.
    Lu Y; Tian M; Liu J; Wang K
    J Biochem Mol Toxicol; 2021 Sep; 35(9):e22848. PubMed ID: 34328678
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.
    Zhu D; Tu M; Zeng B; Cai L; Zheng W; Su Z; Yu Z
    Cancer Med; 2017 Feb; 6(2):452-462. PubMed ID: 28064447
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
    Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
    Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
    [TBL] [Abstract][Full Text] [Related]  

  • 80. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.